Reverse, reverse: Liver disease biotech Hepion and Pharma Two B call off merger

Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of the year.

The decision was mutual, meaning neither company will have to pay a termination fee, according to a Dec. 11 release.